MK7902-001 LEAP-001 (ENGOT-en9)

A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of  Advanced or Recurrent Endometrial Carcinoma (LEAP-001)
Description:
Study Phase: Phase 3
Principal Investigator: Dr Karen Cadoo
Further information

SORAYA IMGN853-0417

A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
Description:
Study Phase: Phase 3
Principal Investigator: Dr Karen Cadoo
Further information

CALLS NGS Mutation Study

A cohort study to establish the prevalence of mutations in patients with CML who meet the ELN criteria for warning or failure and patients with Ph+ ALL with detectable BCR-ABL currently being treated with first or subsequent TKI therapy in the UK using next-generation sequencing
Description:
Study Phase: Other
Principal Investigator: Dr Eibhlin Conneally
Further information

Recruiting Trials

Currently there are no recruiting trials in St James's Hospital for this cancer site. 

 

 

GSK 209229 INDUCE3

A Randomized, Open-label, Adaptive, Phase II/III Study of Pembrolizumab with or without GSK3359609 for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Description:
Study Phase: Phase 2
Principal Investigator: Dr Cliona Grant
Further information

GSK 209227 INDUCE4

A Randomized, Open-label, Phase III Study of GSK3359609 in Combination with Pembrolizumab ± Platinum-based Chemotherapy Doublets versus Pembrolizumab plus 5FU/Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Description:
Study Phase: Phase 3
Principal Investigator: Dr Cliona Grant
Further information

MK-3475-859 (KEYNOTE-859)

A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with previously untreated, HER2 negative, advanced gastric or gastroesophageal junction adenocarcinoma
Description:
Study Phase: Phase 3
Principal Investigator: Prof Maeve Lowery
Further information

MK3475-811 (KEYNOTE 811)

A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab or Placebo as First-line Treatment in Participants With HER2 Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE 811)
Description:
Study Phase: Phase 3
Principal Investigator: Prof Maeve Lowery
Further information

MK3475-756 (KEYNOTE-756)

A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2–) Breast Cancer (KEYNOTE-756)
Description:
Study Phase: Phase 3
Principal Investigator: Dr Sue Sukor
Further information

MK-3475-671 (KEYNOTE-671)

A Phase III, Randomized, Double-blind Trial of Platinum Doublet chemotherapy +/- Pembrolizumab as neo-adjuvant/adjuvant therapy for participants with resectable stage IIb or IIIa non-small cell lung cancer
Description:
Study Phase: Phase 3
Principal Investigator: Sinead Cuffe
Further information

BMS CA209-7FL

A randomized, multicenter, double-blind, placebo-controlled phase 3 Study of Nivolumab Versus Placebo in Combination With neoadjuvant chemotherapy and adjuvant endocrine therapy in the treatment of high-risk, Stage II-III estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer
Description:
Study Phase: Phase 3
Principal Investigator: Dr Sue Sukor
Further information

Astellas_8951-CL-0302 GLOW

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN)  18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
Description:
Study Phase: Phase 3
Principal Investigator: Prof Maeve Lowery
Further information

BMS CA 209-73L

A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer
Description:
Study Phase: Phase 3
Principal Investigator: Dr Sinead Cuffe
Further information

MK-3475 A18 ENGOT-CX11

A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer
Description:
Study Phase: Phase 3
Principal Investigator: Dr Dearbhaile O'Donnell
Further information

IMGN853-0419 PICCOLO

A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
Description:
Study Phase: Phase 2
Principal Investigator: Prof Karen Cadoo
Further information

D8230C00002

A Modular Phase I/II, Open-label, Multicentre Study to Assess AZD4573 in Novel Combinations with Anti-cancer Agents in Patients with Advanced Haematological Malignancies. AZD4573 in Combination with Acalabrutinib in Participants with Relapsed or Refractory DLBCL
Description:
Study Phase: Phase 1
Principal Investigator: Elisabeth Vandenberghe
Further information

ITHACA EFC15992

A Phase 3 randomized, open-label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma
Description:
Study Phase: Phase 3
Principal Investigator: Dr Patrick Hayden
Further information

FEDR-MF-0002 'FREEDOM 2'

A Phase 3, multicentre, Open- Label, randomised study to evaluate the efficacy and safety of Fedratinib compared to Best Available Therapy In Subjects With DIPSS (dynamic international prognostic scoring system) - intermediate or high-risk primary myelofibrosis (PMF), post-polycytemia vera myelofibrosis ( post-PV MF), or post-essential thrombocythemia myelofibrosis (post-ET MF) and previously treated with ruxolitinib
Description:
Study Phase: Phase 3
Principal Investigator: Dr Eibhlin Conneally
Further information

GSK 213831 ZEST

A Randomized Phase 3 Double-Blinded Study Comparing Efficacy of Niraparib to Placebo in Participants with Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer with Molecular Disease Based on Presence of Circulating Tumor DNA after Definitive Therapy
Description:
Study Phase: Phase 3
Principal Investigator: Dr Sue Sukor
Further information

LEAP-015 (MK 7902-015)

A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)
Description:
Study Phase: Phase 3
Principal Investigator: Prof Maeve Lowery
Further information

Versatile

A Phase II, Open-Label, Multi-Center Study of PDS0101 (ImmunoMAPK - RDOTAP/HPV-16 E6 & E7 Peptides) and Pembrolizumab (KEYTRUDA®) Combination Immunotherapy as a First Line Treatment in Subjects with Recurrent and/or Metastatic Head and Neck Cancer and High-RiskHuman Papillomavirus-16 (HPV16) Infection
Description:
Study Phase: Phase 2
Principal Investigator: Cliona Grant
Further information

BGB-3111-306

A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
Description:
Study Phase: Phase 3
Principal Investigator: Prof Elisabeth Vandenberghe
Further information

DESTINY-Breast05 DS8201-A-U305

A phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in subjects with high-risk HER2-positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes following neoadjuvant therapy
Description:
Study Phase: Phase 3
Principal Investigator: Dr Sue Sukor
Further information

Oasis-4

A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms
Description:
Study Phase: Phase 3
Principal Investigator: Dr Ciara O'Hanlon Brown
Further information

Trio-Lidera

A Phase III, Randomized, Open Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor Positive, HER2 Negative Early Breast Cancer
Description:
Study Phase: Phase 3
Principal Investigator: Dr Ciara O'Hanlon Brown
Further information

Sascia

Phase III postneoadjuvant study evaluating Sacituzumab Govitecab, an antibody drug conjugate in primary HER2-negative breact cancer patients with high relapse rate after standard neoadjuvant treatment
Description:
Study Phase: Phase 3
Principal Investigator: Ciara O'Hanlon Brown
Further information

CA209 8HW (CheckMate 8HW)

A Phase 3b Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer
Description:
Study Phase: Phase 3
Principal Investigator: Prof David Gallagher
Further information

LITHIUM

A Phase Ib, Dose Escalation Study of Lithium when added to standard chemotherapy of Oxaliplatin and Capecitabine in Patients with Advanced Oesophago-Gastric or Colorectal Cancer.
Description:
Study Phase: Phase 1
Principal Investigator: Prof Maeve Lowery
Further information

LITHIUM

A Phase Ib, Dose Escalation Study of Lithium when added to standard chemotherapy of Oxaliplatin and Capecitabine in Patients with Advanced Oesophago-Gastric or Colorectal Cancer.
Description:
Study Phase: Phase 1
Principal Investigator: Prof Maeve Lowery
Further information

Mk3475-C93

A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15)
Description:
Study Phase: Phase 3
Principal Investigator: Prof Karen Cadoo
Further information

Mk3475-B96

A Phase 3, Randomized, Double Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum resistant Recurrent Ovarian Cancer
Description:
Study Phase: Phase 3
Principal Investigator: Dr Karen Cadoo
Further information

HOVON 156

A Phase 3, Multicenter, open-label, Randomized, Study of Gilteritinib versus Midostaurin in Combination with Induction and Consolidation Therapy followed by one-year maintenance in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) or myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 Mutations Eligible for Intensive Chemotherapy
Description:
Study Phase: Phase 3
Principal Investigator: Eibhlin Conneally
Further information

LOXO-BTK-20019 (BRUIN MCL-321)

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma
Description:
Study Phase: Phase 3
Principal Investigator: Prof Elisabeth Vandenberghe
Further information

MO40598 POLARGO

A phase II, open-label, multicenter, randomized study evaluating the safety and efficacy of polatuzumab vedotin in combination with rituximab plus gemcitabine plus oxaliplatin (r-gemox) versus r-gemox alone in patients with relapsed/refractory diffuse large b-cell lymphoma
Description:
Study Phase: Phase 2
Principal Investigator: Prof Elisabeth Vandenberghe
Further information

MOR208C310 (frontMIND)

A Phase 3, multicenter, randomized, double-blind, placebocontrolled trial comparing the efficacy and safety of Tafasitamab plus Lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and highrisk patients with newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Description:
Study Phase: Phase 3
Principal Investigator: Prof Elisabeth Vandenberghe
Further information

Dreamm-14

A Phase II, Randomized, Parallel, Open-Label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-Agent Belantamab Mafodotin (GSK2857916) in Participants with Relapsed or Refractory Multiple Myeloma (DREAMM-14)
Description:
Study Phase: Phase 2
Principal Investigator: Patrick Hayden
Further information

CARTITUDE-5

A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Description:
Study Phase: Other
Principal Investigator: Dr Larry Bacon
Further information

MK-3475-689 (KEYNOTE-689)

A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
Description:
Study Phase: Phase 3
Principal Investigator: Dr Cliona Grant
Further information

M14-239

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
Description:
Study Phase: Phase 2
Principal Investigator: Dr Sinead Cuffe
Further information

ZEAL-1L

A Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants with Advanced/Metastatic Non-Small Cell Lung Cancer.
Description:
Study Phase: Phase 3
Principal Investigator: Dr Sinead Cuffe
Further information

MK7684A-008

A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer
Description:
Study Phase: Phase 3
Principal Investigator: Dr Sinead Cuffe
Further information

Mirati Krystal-12

A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
Description:
Study Phase: Phase 3
Principal Investigator: Dr Sinead Cuffe
Further information

LOXO-BTK-20020 (BRUIN CLL-321)

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Description:
Study Phase: Phase 3
Principal Investigator: Prof Elisabeth Vandenberghe
Further information

MK3475-B49

A phase 3 study looking at pembrolizumab plus chemotherapy versus placebo + chemotherapy for the treatment of chemotherapy-candidate HR+/HER2- locally recurrent inoperable or metastatic breast cancer.
Description:
Study Phase: Phase 3
Principal Investigator: Dr Ciara O'Hanlon Brown
Further information

AcceleRET-Lung / BO42864 (formerly BLU-667-2303)

A Randomized, Open-Label, Phase 3 Study of Pralsetinib Versus Standard of Care Plt-based Chemotherapy for First Line RET Fusion-positive, Metastatic Non-Small Cell Lung Cancer
Description:
Study Phase: Phase 3
Principal Investigator: Dr Sinead Cuffe
Further information

MK-3475 630

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab versus placebo as adjuvant therapy following surgery and radiation in participants with high-risk locally advanced cutaneous squamous cell
Description:
Study Phase: Phase 3
Principal Investigator: Dr Cliona Grant
Further information

MK7684A-010

A Phase 3, Randomised, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)
Description:
Study Phase: Phase 3
Principal Investigator: Dr Fergal Kelleher
Further information

Fortitude

A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression
Description: This double-blind trial assesses the effectiveness of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in patients Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b overexpression
Study Phase: Phase 3
Principal Investigator: Prof Maeve Lowery
Further information

Destiny Gastric04 DS8201-A-U306

A Phase 3, multicenter, 2-arm randomized, open-label study of trastuzumab deruxtecan in subjects with HER2-positive metastatic and/or unresectable gastric or gastro-esophageal junction (GEJ) adenocarcinoma subjects who have progressed on or after a trastuzumab-containing regimen
Description: This 2-arm trial will assess the effectiveness of trastuzumab deruxtecan v's Ramucirumab + Paclitaxel in patients with locally advanced, recurrent or metastatic gastric cancer or gastro-esophageal junction
Study Phase: Phase 3
Principal Investigator: Prof Maeve Lowery
Further information

ACE-536-MF-002 (INDEPENDENCE)

A Phase 3, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm- Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
Description: This is a double-blind trial that assesses the effectiveness of Luspatercept v's Placebo in patients with Myeloproliferative Neoplasm- Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
Study Phase: Phase 3
Principal Investigator: Dr Eibhlin Conneally
Further information

Summit

A MULTI-PART, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 CLINICAL STUDY OF THE SAFETY AND EFFICACY OF CGT9486 IN SUBJECTS WITH NONADVANCED SYSTEMIC MASTOCYTOSIS
Description: This is a placebo controlled trial that assesses the effectiveness of CGT9486 in patients with non-advanced systemic mastocytosis.
Study Phase: Phase 3
Principal Investigator: Dr Eibhlin Conneally
Further information